Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing
has proven that its DehydraTECH(TM) technology delivers cannabinoids to the
bloodstream much more quickly and effectively than conventional industry
formulations. According to the update, 10 male Sprague-Dawley rats were
administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal
studies. Delivery of CBD into the bloodstream was monitored over a 60-minute
duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH’s LCFA
formulation delivered elevated levels of CBD in blood (showing measurable and
475% and 319% greater levels, respectively) as compared to a medium chain
triglyceride (“MCT”) oil formulation. Over the entire 60-minute study, the
standard DehydraTECH LCFA formulation achieved an average maximum CBD blood
concentration level that was 334% more than the average maximum blood
concentration level of the MCT oil formulation.
To view the full press release, visit http://ibn.fm/ZEiNG
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology, which promotes healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has multiple patents pending in over 40 countries around the world and
has patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
